Mahanimbine

Mahanimbine

SCHEMBL18488200

CC(C)=CCC[C@]1(C)C=Cc2c(c(C)cc3c2[nH]c2ccccc23)O1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ MAPT P10636 4/20 1.00
▸ KMT2A Q03164 3/20 1.00
▸ MEN1 O00255 2/20 1.00
▸ PNLIP P16233 1/20 1.00
▸ POLB P06746 2/20 0.79
▸ XBP1 P17861 2/20 0.79
▸ GAA P10253 2/20 0.79
▸ NPSR1 Q6W5P4 2/20 0.79
▸ IDE P14735 1/20 0.79
▸ NPC1 O15118 1/20 0.63
▸ RAB9A P51151 1/20 0.63
▸ MAPK1 P28482 1/20 0.59
▸ ATM Q13315 1/20 0.59
▸ ALOX5 P09917 1/20 0.51
▸ PTGS1 P23219 1/20 0.51
▸ APP P05067 2/20 0.42
▸ NR1H4 Q96RI1 4/20 0.41
▸ BACE1 P56817 1/20 0.41
▸ TRPA1 O75762 1/20 0.40
▸ LDHA P00338 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Mahanimbine SCHEMBL2991765 1.00 MAPT (1.00) MAPTKMT2AMEN1PNLIPPOLB
Mahanimbine SCHEMBL18488203 1.00 MAPT (1.00) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL20434657 0.89 MAPT (0.84) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL13142229 0.88 MAPT (1.00) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL18317471 0.88 MAPT (1.00) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL13344164 0.88 MAPT (1.00) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL31723092 0.86 MAPT (0.73) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL31723084 0.81 MAPT (0.71) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL25937950 0.80 MAPT (0.72) MAPTKMT2AMEN1PNLIPPOLB
SCHEMBL30366382 0.79 KMT2A (0.66) MAPTKMT2AMEN1PNLIPPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200247751-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2020-08-06 — — US disclosed
US-20190077755-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2019-03-14 — — US disclosed
US-10173978-B2 Small molecule androgen receptor inhibitors and methods of use thereof GEORGETOWN UNIVERSITY (US) 2019-01-08 — — US disclosed
US-20180215712-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2018-08-02 — — US disclosed
US-20180215712-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2018-08-02 — — US disclosed
WO-2017023916-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF GEORGETOWN UNIVERSITY (US) 2017-02-09 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180215712-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF AR, KLK3, BRDT MAPT 3890/4885KMT2A 1054/4885MEN1 3004/4885
US-20190077755-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF AR, KLK3, BRDT MAPT 3890/4885KMT2A 1054/4885MEN1 3004/4885
US-20200247751-A1 SMALL MOLECULE ANDROGEN RECEPTOR INHIBITORS AND METHODS OF USE THEREOF AR, KLK3, BRDT MAPT 3890/4885KMT2A 1054/4885MEN1 3004/4885
US-10173978-B2 Small molecule androgen receptor inhibitors and methods of use thereof AR, KLK3, BRDT MAPT 3890/4885KMT2A 1054/4885MEN1 3004/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback